Multiple sclerosis and related disorders: Short report peripheral vascular events in a real-world cohort of multiple sclerosis patients using Fingolimod.
Adverse events
Disease-modifying treatment
Fingolimod
Multiple sclerosis
Peripheral vascular events
Thrombosis
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
03
06
2020
revised:
07
07
2020
accepted:
16
07
2020
pubmed:
28
7
2020
medline:
15
5
2021
entrez:
26
7
2020
Statut:
ppublish
Résumé
Fingolimod is a high-efficacy disease-modifying therapy for multiple sclerosis (MS) and was the first oral treatment approved for the disease. Adverse events include bradyarrhythmia, hypertension, macular oedema and increased risk of infections, mainly due to its main mechanism of action, the non-selective modulation of sphingosine-1-phosphate receptor. We report the baseline characteristics, effectiveness outcomes and adverse events of a prospective cohort of 177 patients with a median treatment duration of 24 months, in which four patients (2.3%) presented with otherwise non-provoked peripheral vascular events (PVE). Further studies are still needed to evaluate the frequency and severity of PVE in fingolimod patients.
Sections du résumé
BACKGROUND
BACKGROUND
Fingolimod is a high-efficacy disease-modifying therapy for multiple sclerosis (MS) and was the first oral treatment approved for the disease. Adverse events include bradyarrhythmia, hypertension, macular oedema and increased risk of infections, mainly due to its main mechanism of action, the non-selective modulation of sphingosine-1-phosphate receptor.
METHODS AND RESULTS
RESULTS
We report the baseline characteristics, effectiveness outcomes and adverse events of a prospective cohort of 177 patients with a median treatment duration of 24 months, in which four patients (2.3%) presented with otherwise non-provoked peripheral vascular events (PVE).
CONCLUSIONS
CONCLUSIONS
Further studies are still needed to evaluate the frequency and severity of PVE in fingolimod patients.
Identifiants
pubmed: 32711299
pii: S2211-0348(20)30486-7
doi: 10.1016/j.msard.2020.102411
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Fingolimod Hydrochloride
G926EC510T
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
102411Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest EC received the ECTRIMS Clinical Fellowship (2013-2014), ECTRIMS travel grant awards, and academic travel support from Novartis, Genzyme, Merck, Biogen and Roche, has been a member of advisory boards at Genzyme, Biogen, Merck and Novartis, has received sub-investigator fees from the ISS “Social Cognition in MS” project at Teva and sub-investigator fees from project CORFO 14PIE-26946 - InnoBioscience SpA. RUSM received academic travel support from Novartis, Genzyme, Merck, Biogen and Roche, has been a member of advisory boards at Genzyme, Biogen, Merck and Novartis. CC received academic travel support from Novartis, Genzyme, Merck, Biogen and Roche, has been a member of advisory boards at Genzyme, Biogen, Merck and Novartis, has received PI fees from the ISS “Social Cognition in MS” project at Teva, and PI fees from project CORFO 14PIE-26946 - InnoBioscience SpA. CP nothing to disclose. BS received academic travel support from Novartis, Teva, Merck and Biogen AR and EV nothing to disclose.